Price Alert: Shares of Kiromic (KRBP) Trade 5.48% Higher at Midday June 23

Equities Staff  |

Today Kiromic BioPharma Inc (NASDAQ: KRBP) is trading 5.48% up.

The latest price, as of 11:54:22 est, was $0.51. Kiromic has moved $0.0263 in trading today.

68,966 shares have exchanged hands.

As of the previous close, Kiromic has a YTD change of 68.60%. The company expects its next earnings on 2022-08-12.

For technical charts, analysis, and more on Kiromic visit the company profile.

About Kiromic BioPharma Inc

Kiromic BioPharma, Inc. is an immuno-oncology biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. The pipeline development is leveraged through the Company's proprietary target discovery engine called 'DIAMOND.' Kiromic's DIAMOND is essentially big data science meeting target identification, dramatically compressing the man-years and the millions of drug development dollars needed to develop a live drug. The Company's headquarters are located in Houston, TX adjacent to the world's largest medical center and the MD Anderson Cancer Center.

To get more information on Kiromic BioPharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Kiromic BioPharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content